PHARNEXT (EPA:ALPHA) Pharnext refocuses its clinical trial programs on PXT3003, its most promising drug candidate, to optimize financial resources allocation
Transparency directive : regulatory news
14/02/2023 08:30
PHARNEXT's latest news
28/02/2024 08:30
19/12/2023 08:00
11/12/2023 08:30
27/11/2023 08:30
23/11/2023 08:30
26/09/2023 10:30
20/09/2023 08:30
24/08/2023 08:30
12/05/2023 08:30
23/03/2023 08:30
Other stories
17/05/2024 11:14
17/05/2024 11:42
17/05/2024 11:00
16/05/2024 22:32
17/05/2024 08:01
17/05/2024 11:22
17/05/2024 12:22
17/05/2024 06:00
17/05/2024 03:26
17/05/2024 11:12
17/05/2024 05:16
17/05/2024 10:40
16/05/2024 19:22
17/05/2024 08:37
17/05/2024 11:15
17/05/2024 08:33
17/05/2024 10:34
17/05/2024 09:31
16/05/2024 17:10
16/05/2024 23:01
16/05/2024 18:24
16/05/2024 20:27
17/05/2024 06:02
17/05/2024 01:45
17/05/2024 09:04
17/05/2024 11:03
17/05/2024 07:02
17/05/2024 12:02
Jurgen Klopp's parting promise to 'special city' ahead of final game as Liverpool manager - Sky News
17/05/2024 07:50
17/05/2024 11:06
17/05/2024 07:36
16/05/2024 11:05
15/05/2024 11:19
15/05/2024 17:00
17/05/2024 11:33
16/05/2024 16:36
17/05/2024 07:10
16/05/2024 10:15